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behavioural intervention for men who have hot
flushes following prostate cancer treatment
(MANCAN): trial protocol
Omar Yousaf1, Evgenia Stefanopoulou1, Elizabeth A Grunfeld2 and Myra S Hunter1*Abstract
Background: This randomised controlled trial (RCT) aims to evaluate the effectiveness of a guided self-help
cognitive behavioural intervention to alleviate problematic hot flushes (HF) and night sweats (NS) in men who are
undergoing prostate cancer treatment. The trial and the self-help materials have been adapted from a previous RCT,
which showed that a cognitive behavioural intervention reduced the self-reported problem-rating of hot flushes in
women with menopausal symptoms, and in women undergoing breast cancer treatment. We hypothesize that
guided self-help will be more effective than usual care in reducing HF/NS problem-rating at post treatment
assessment.
Methods/Design: Seventy men who are undergoing treatment for prostate cancer and who have been
experiencing more than ten HF/NS weekly for over a month are recruited into the trial from urology clinics in
London. They are randomly allocated to either a four-week self-help cognitive behavioural therapy (CBT) treatment
or to their usual care (control group). The treatment includes information and discussion about hot flushes and
night sweats in the context of prostate cancer, monitoring and modifying precipitants, relaxation and paced
respiration, stress management, cognitive therapy for unhelpful thoughts and beliefs, managing sleep and night
sweats, and advice on maintaining these changes.
Prior to randomisation, men attend a clinical interview, undergo 24-48-hour sternal skin conductance monitoring,
and complete pre-treatment questionnaires (e.g., problem-rating and frequency of hot flushes and night sweats;
quality of life; mood; hot flush beliefs and behaviours). Post-treatment measures (sternal skin conductance and the
above questionnaires) are collected four-six weeks later, and again at a six-month follow-up.
Discussion: MANCAN is the first randomised controlled trial of cognitive behavioural therapy for HF/NS for men
that measures both self-reported and physiologically indexed symptoms. The results will inform future clinical
practice by evaluating an evidence-based, non-medical treatment, which can be delivered by trained health
professionals.
Trial registration: UK Clinical Research Network UKCRN10904.
Keywords: Oncology, Cancer, Prostate, Self-help, Cognitive behaviour therapy, Protocol, RCT* Correspondence: myra.hunter@kcl.ac.uk
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Prostate cancer is the most common cancer among men
in the UK and the incidence rate has increased in the last
30 years, mainly due to improvements in the detection
of the disease. While the five-year survival rate in the
UK is good, prostate cancer survivors often face un-
wanted treatment side-effects, which are particularly
troublesome following androgen deprivation therapy
(ADT) [1]. Hot flushes and night sweats (HF/NS) are
one of the main side-effects of ADT [2,3]. They are tran-
sitory sudden periods of heat and sweating lasting be-
tween two and ten minutes, generally on the neck, face
and torso [4] The causal mechanism of HF/NS in men
remains poorly understood, however, as for women, they
are associated with changing hormone levels. A sudden
change in levels of androgens is believed to alter the
function of brain neurotransmitters (serotonin, noradre-
nalin and beta-endorphins), which in turn may lead to
instability of the set point of the thermoregulatory centre
in the hypothalamus. Intermittently, or in response to in-
ternal or external stimuli, the hypothalamus may down
regulate body temperature by sweating and vasodilation
[5].
HF/NS in men are under-researched compared to
those experienced by menopausal women or women fol-
lowing breast cancer treatments. Up to 80% of men hav-
ing ADT report HF/NS and these tend to be more
frequent and severe than those experienced by women
[6]. They can also be persistent; in one study over 40% of
patients experienced HF/NS eight years post-treatment
[7]. HF/NS are associated with distress and reduced
quality of life – particularly affecting sleep and physical
well-being [8]. The management of these symptoms pre-
sents a challenge to patients and clinicians alike. A
recent systematic review of treatments for HF/NS in
prostate cancer patients concluded that only a few
treatments are available that are both effective and well
tolerated, that more randomised controlled trials are
needed, and that a priority should be the development of
acceptable and effective treatments that are free from
side-effects [5].
We have developed non-medical interventions for
HF/NS [9,10] and a theoretical model of HF/NS [11].
This work identifies a range of factors that can moderate
the intensity and experience of HF/NS, such as certain
triggers (e.g., hot foods and drinks), stress, and cogni-
tive/behavioural responses. There is evidence from la-
boratory studies with women that stressors increase the
general level of HF reporting [12] and anxiety [13]. Also,
unhelpful cognitions - that is negative thoughts asso-
ciated with embarrassment, social anxiety, feeling out of
control and unable to cope - are associated with more
problematic HF/NS and sleep problems [14]. A psycho-
logical intervention, based on cognitive behaviour therapy(CBT) has been developed in the UK for women who
have problematic HF/NS during the menopause transi-
tion [9] and for women following breast cancer treat-
ment [10]. This has been found to be effective in
reducing hot flush problem-rating (the extent to which
they are problematic) in two recently published RCTs
with breast cancer patients (MENOS1) [15] and well
women (MENOS2) [16]. In MENOS2 both group CBT
and guided self-help CBT were significantly more effect-
ive than no treatment, suggesting that a self-help format
may be acceptable and beneficial. There is evidence that
prostate cancer patients might prefer individualised in-
formational support [17]; furthermore telephone support
services are well received by men and guided self-help
can be accessed by men living at a distance or who are
housebound.
Current study
This study aims to evaluate the effectiveness of guided
self-help to alleviate HF/NS in men following treatment
for prostate cancer. Guided self-help is compared to
usual care (access to nurses and/or telephone support
service) in a randomized controlled trial, using both
physiological (sternal skin conductance [SSC]) and sub-
jective measures of HF/NS and a 6 month follow-up. We
hypothesise that guided self-help is more effective than
usual care in reducing HF/NS problem-rating. Secondary
analyses will also examine the effects of the treatment on
HF/NS frequency, mood and quality of life (QOL). Medi-
ating variables, including physiological HF/NS, beliefs
and behaviours, are examined. A one year follow-up will
be carried out by telephone off trial to estimate longer
term outcomes. If effective, the treatment can be pro-
moted by publication of the treatment manual and by
training and supervising clinical nurse specialists in the
application of the treatment.
The trial is funded by the Prostate Cancer Charity, and
registered with the UK Clinical Research Network
(UKCRN; Trial ID: 10904). NHS REC approval has been
granted (South East London 2 REC, ref: 11/LO/1114)
and local ethics and R&D approval has been obtained for
recruitment of prostate cancer patients from all hospitals
in the South East London Cancer Research Network
(SELCRN).
Methods/Design
Study sample and recruitment
Inclusion criteria
Prostate cancer patients aged above 18, English-speaking,
who have had more than 10 HF/NS weekly for at least
one month will be included. Furthermore, screening takes
place to ensure that patients consider their HF/NS prob-
lematic, and that their participation in the trial is moti-
vated by their concerns about HF/NS and not any other
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gling with.
Patients are recruited into the treatment study by Pros-
tate Cancer Nurse Specialists and Cancer Care Managers
(Surviving Cancer Living Life telephone support service)
at Guy's & St Thomas' NHS Foundation Trust, who pro-
vide a service to prostate cancer patients throughout the
South East London Cancer Network. This catchment
area includes a high proportion of African Caribbean
men who are more likely to have prostate cancer. The
men are contacted through medical staff at the clinics,
and, after completing a telephone screening interview to
assess inclusion criteria, they are provided with informa-
tion about the study (verbal and written information
about the two arms of the trial). Consent is then
obtained for participation in the study (with a 2-week
time interval). Following consent, they are invited for an
interview where questionnaires are completed, and they
are informed about their group allocation (guided self-
help or usual care).
Procedure
The intervention: The guided self-help treatment is a
4-week intervention consisting of a booklet with infor
mation about prostate cancer and HF/NS, cognitive/be-
havioural exercises, and a CD with information, relax-
ation and paced breathing instructions. The approach
is psycho-educational with individual treatment goals
and an active focus upon cognitive and behavioural
changes. The treatment includes:
 Information about causes of and factors affecting
HF/NS.
 Monitoring and modifying precipitants, e.g. spicy
food, alcohol.
 Relaxation and paced breathing, to reduce stress and
apply at onset of HF/NS.
 Cognitive therapy for unhelpful thoughts and beliefs
about HF/NS.
 Behavioural strategies to reduce stress and deal with
HF/NS in social situations.
 Managing sleep and NS, drawing upon CBT for
insomnia.
 Managing HF/NS and maintaining changes in the
context of having prostate cancer.
At the initial assessment, which takes place in the
Health Psychology department of King's College London
at Guy's Hospital, the booklet is introduced and the pa-
tient is shown the paced breathing exercises. They are
encouraged to discuss the treatment with their partner,
family or friends. Two and four weeks later telephone
interviews are held to discuss progress. Six weeks follow-
ing assessment they are invited for a repeat assessment.Usual care: The control arm receives standard care –
they have access to their urologist and clinical nurse spe-
cialist, as well as cancer information and telephone
support services. They thus have access to support and
to existing written and verbal information about deal-
ing with hormone related treatment side-effects. Once
their participation in the trial ends, participants in the
usual care group will be offered the intervention if they
are interested.
Randomisation is carried out using the software Rand.
exe version 6, which randomises participants to one of
the two groups. Blocked stratification is used to ensure
that the two groups do not differ on the potentially mod-
erating variable of cancer type; depending on whether
patients have localized or metastatic cancer (i.e., one that
has spread to other organs), the intervention might be
more or less effective. Patients with metastatic cancer
may have lower levels of functioning and be less amen-
able to the intervention. Hence, stratifying for cancer
type balances out any effects that might be due to this
variable. Treatments undertaken during the follow-up
period will be monitored in both arms of the trial.
Blinding: During the screening and baseline assess-
ments the clinical psychologist is blind to group alloca-
tion. After this, the researcher generates a randomised
allocation using Rand.exe and sends this to the clinical
psychologist who in the next meeting informs the patient
of allocation and then either starts the intervention or
informs patients that they will continue with their usual
care. The post-intervention assessments are then carried
out by the researcher who is blind to group allocation.
Figure 1 shows the trial procedure.
Measures
Socio-demographics
In the initial meeting the following data are registered:
date of birth, height, weight, ethnicity, number of chil-
dren, level of education, marital status, employment
status, smoking, drinking, exercise participation, medica-
tion, and medical treatment history (including any treat-
ments for HF/NS).
Primary outcome
The self-reported problem-rating of HF/NS (Hot Flush
Rating Scale, or HFRS [18]) at post treatment will consti-
tute the primary outcome; the score is the mean of 3
items (i.e., ‘To what extent do you regard your flushes/
sweats as a problem?’, ‘How distressed do you feel about
your hot flushes?’, and ‘How much do your hot flushes
interfere with your daily routine?’) are rated on a 10-
point Likert scale where a higher score indicates that the
patient views his HF/NS as highly bothersome and inter-
fering with life. A difference of 2 points or more is con-
sidered clinically relevant [9,10,19].The scale has good
Referred to study by CNS and Cancer care managers 
and recruited into the study:
Screening questionnaire, interview, information sheet and consent
Completed 2 week daily diaries 
RANDOMISATION
Pre-treatment questionnaires and HF monitor
GUIDED SELF HELP USUAL CARE
1-2 telephone
contacts Usual care
Post treatment questionnaires 
and HF monitor
Post treatment questionnaires 
and HF monitor
Follow-up questionnaires 
6 months post treatment
Follow-up questionnaires 
6 months post treatment
Figure 1 Study flowchart showing allocation to groups.
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alpha=0.9) and test-retest reliability (r = 0.8). The
problem-rating is chosen as the prime outcome measure
because it, rather than frequency, is associated with
help-seeking and quality of life, and in recent studies
problem-rating has been recommended as the most ap-
propriate patient reported outcome measure in clinical
trials of HF/NS treatments [20,21]. Problem-rating and
severity tend to be correlated and neither are strongly
associated with frequency of HF/NS [21].Secondary outcomes
The problem-rating of HF/NS described above will be
measured again at the 6-month follow-up session as a
secondary outcome.
Self-reported frequency of HF/NS is assessed by a
subscale of the HFRS which measures the total number
of HF/NS reported in the past week. This subjective
HF/NS frequency measure was found to correlate
(r = 0.9, p< 0.0001) with daily diary recordings of HF/
NS in a previous study [18].
Quality of life (QOL) is assessed using both the 30-
item EORTC QLQ-C30 [22] which is a standardised
measure of QOL in cancer patients in general (including
questions about physical and mental functioning and
well-being), and the 25-item EORTC QLQ-PR25 [23]
which is a prostate cancer-specific measure (whichincludes questions about urinary symptoms, sexual func-
tion, hormonal treatment-related symptoms etc.).
Mood is measured using the 14-item Hospital Anxiety
and Depression Scale (HADS, [24]) which has two sub-
scales for depressed mood and anxiety and was devel-
oped for use with medical samples. We expect that the
intervention will have an effect on mood because hot
flushes negatively affect patients’ mood and well-being.
Frequency of HF/NS, QOL and mood will all be mea-
sured at post-treatment and at the 6-month follow up as-
sessment. Health economics questions, adapted from
Beecham & Knapp [25]), including items on the number
of consultations at primary and secondary care, absence
from work, medical and non-medical treatments used
across the duration of the trial, will be completed at the
6-month follow-up session.
Moderators
The 11-item Constructed Meaning Scale (CMS; [26])
measures whether, and/or how much, having a cancer
diagnosis affects the way people feel about themselves,
their relationships, and the future. We will examine
whether men’s views about prostate cancer affect their
response to the self-help treatment for HF/NS. This scale
has previously been used in studies of people with cancer
who vary in their tendency to perceive their cancer as a
major threat [27], so there is a theoretical reason to pre-
dict that it might moderate the effectiveness of the
intervention
The 4-item Emotional Control subscale of the Barriers
to Help Seeking Scale (EC of the BHSS; [28]) measures a
person’s willingness to express feelings and negative emo-
tions. Including this measure enables us to explore
whether beliefs about emotions are associated with out-
come of the self-help treatment. Patients who are less will-
ing to express emotions might be less amenable to the
intervention which encourages an awareness of the rela-
tionships between cognitions, emotions and behaviours.
The 10-item Somatosensory Amplification Scale
(SSAS; [29]) measures how sensitive individuals are to
changes in their bodies. Including this as a moderator
variable allows us to test whether heightened sensitivity
affects the efficacy of the treatment. HF/NS may be exa-
cerbated by an increased awareness of and attention to
the body, so individuals who score highly on this scale
might find it more difficult to follow some of the techni-
ques of the treatment which aim to reduce attentional
focus to HF/NS.
Finally, we employ the 10-item Revised Life Orienta-
tion Test (LOT-R; [30]) to examine whether trait opti-
mism moderates the treatment outcome. This scale is
used to assess how positive individuals’ outlook on life is,
with a low score indicative of pessimism with regards to
life events. Hence, individuals with low scores are not
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individuals with high scores on this scale.
Mediators
The Hot Flush Beliefs Scale [14] and The Hot Flush Be-
havior Scale [31] are used both before and after the treat-
ment to check for any mediation effects. The scales,
which were originally used for women with menopausal
symptoms, have been modified for men (reduced to a
combined total of 22 items). They measure types of
beliefs and behaviours of individuals with HF/NS, some
of which appear to be helpful and other less helpful [31].
Inclusion of these variables will help to clarify how the
CBT intervention is working, i.e. whether specific beliefs
and behaviours show change at post treatment and me-
diate improvement at follow-up.
The frequency of HF/NS is also measured by 24-48-
hour ambulatory SSC monitoring (Bahr SSC monitor
[Simplex Scientific; Middleton, WI, USA]) before and
after treatment. The impact of the treatment upon sub-
jective (frequency and problem-rating) and physiological
measure of frequency will be an important secondary
analysis and will help us to understand whether treat-
ments are affecting the HF/NS threshold and/or symp-
tom perception. We also record the self-reported
frequency of relaxation practice, as well as treatment effi-
cacy beliefs.
Statistical analysis
Primary efficacy analysis will be performed on the intent
to treat population. The problem-rating of HF/NS at post
treatment will be analysed using ANCOVA (i.e., analysis of
covariance), adjusting for baseline problem-rating.
Secondary efficacy analyses: Secondary outcomes will
be compared between groups as above. Possible media-
tors to response will also be investigated. The person
performing the analyses will remain blind to the treat-
ment grouping.
Safety analysis: The prevalence of specific adverse events
is recorded and groups will be compared post-treatment.
Economic analysis: A descriptive analysis of economic
data will be performed.
Statistical support may be sought from the Biostatistics
Department, Institute of Psychiatry, King’s College Lon-
don. Statisticians will not be informed of group allocation.
Power calculation: The sample size is calculated on the
HF/NS Problem Rating Scale, estimating a mean of 5
(SD= 2.4) and a clinically relevant difference of 2 points
[9]. A total sample size of 50, 25 in each group (allowing
for 20% attrition) will have 90% power to detect a differ-
ence in mean HF/NS Problem-rating of 2 (a clinically
significant change); based on results with women (no
data on men exists) mean change of 2.87 and 0.77 in
treatment and control groups respectively. However, wewill recruit 70 (35 in each group) in order to power for
secondary analyses, e.g. HF/NS frequency. We are
recruiting from sites in the South East London Cancer
Network and have badged the project with the NCRN.
We estimate that 200 men receive ADT per year, that
35% (70) will meet inclusion criteria and that 16 months
of recruitment should provide the numbers needed.
Discussion
This study is a randomised controlled trial of cognitive
behavioural therapy to treat hot flushes and/or night
sweats experienced by prostate cancer patients currently
undergoing treatment. The trial, due to its non-medical
nature, might provide an acceptable alternative to med-
ical treatments some of which have unwelcome side-
effects [5]. The trial has been carefully designed to target
key components that might reduce the impact of HF/NS
[11]. We will be able to assess whether a four-week self-
help CBT treatment results in significant improvements
over usual care in terms of both self-reported and
physiological measures of HF/NS.
We expect that guided self-help CBT will be more ef-
fective than usual care in reducing HF/NS problem-
rating and secondary analyses will examine the effects
of the treatment on HF/NS frequency, mood and qual-
ity of life (QOL). Moderators and mediating variables
are examined including physiological HF/NS, beliefs and
behaviours. A one year follow-up will be carried out by
telephone off trial to estimate longer term outcomes. If
effective, the treatment can be promoted by publication
of the treatment manual and by training and supervis-
ing clinical nurse specialists in the application of the
treatment.
Methodological considerations
One of the strengths of the trial is that the intervention
has been adapted from our previous work which proved
successful in reducing the problem-rating and frequency
of HF/NS in women [15,16]. There is no theoretical rea-
son for differences in the mechanisms and triggers of
HF/NS in men and women, so while the materials for
the present intervention have been modified to suit men,
the CBT components and focus on paced breathing and
relaxation remain the same. The treatment is that it is
standardised and replicable through the clearly specified
manual, which step-by-step outlines how to deliver it
according to the protocol. This will be important if and
when the treatment is used in the future by trained
health professionals.
Efforts have been made to include self-reported out-
come measures that are directly related to the aspects
that the intervention addresses. In addition, the inclusion
of the physiological measure adds a more objective
measurement of treatment efficacy. In terms of the study
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from both African Caribbean and White British
backgrounds.
A limitation of the trial is that the usual care group,
which serves as the control group, does not have any
new treatment associated with it, which reduces its com-
parability to the self-help group. It may be the case that
seeing a clinical psychologist and receiving two tele-
phone calls, reduces the severity of HF/NS by, for ex-
ample, reducing stress and uncertainty. Therefore, it
would have been ideal with a control condition, e.g. a
booklet with some non-CBT activities, to show that it is
the self-help CBT, and not merely the support and atten-
tion, that reduces the problem-rating of HF/NS. How-
ever, this is an exploratory RCT and if CBT is found to
be effective future research might include additional
controls.
Another limitation of the trial is that of demand char-
acteristics; patients might report improvements in the
outcome measures simply to please the researchers. To
reduce this problem, we ensure at the stage of the initial
screening and first meeting that we do not present the
trial as a stand-alone solution to their HF/NS but instead
explain that the goal of the study is to assist patients in
managing their symptoms, and not eliminating them.
Also, we do not tell patients what the main outcome
measure is.
Conclusion
Prostate cancer survivors who are experiencing problem-
atic HF/NS have few acceptable and effective treatment
options that are free from side-effects. Cognitive behav-
ioural therapy has shown significant reductions in HF/
NS problem-rating and frequency in women [15,16].
This study is a randomised controlled trial of guided
self-help CBT for HF/NS which includes both self-
reported and physiological outcome measures. The trial
tests for treatment effects on HF/NS, sleep, mood and
health related quality of life. If effective, the CBT treat-
ment for HF/NS might then be implemented widely by
health professionals with relevant training and
supervision.
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